MOTS-c
Research OnlyAlso known as: Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide, MOTS-C peptide
A 16-amino acid mitochondrial-derived peptide encoded in mtDNA that targets AMPK/mTOR pathways for metabolic regulation. Preclinical studies show exercise mimetic and geroprotective effects. Lower MOTS-c levels found in T2D patients. No clinical trials yet conducted in humans.
Research Statistics
Mitochondria-derived metabolic peptide with growing international interest and small human dataset; AMPK activation mechanism is supported by preclinical data but human validation is early-stage.
Research Dossier
Overview
What is MOTS-c and what does the research say?
Mechanism of Action
MOTS-c is a mitochondria-derived peptide (MDP) discovered in 2015, encoded within the 12S rRNA gene of mitochondrial DNA. It functions as a metabolic regulator that coordinates cellular and whole-body energy homeostasis.
How It Works (Simplified)
MOTS-c acts as an “exercise mimetic” through metabolic pathway activation:
Activates the “master metabolic regulator” AMPK, shifting cells from growth mode to maintenance and repair - the same pathway activated by exercise.
Indirectly inhibits mTOR through AMPK, promoting autophagy (cellular cleanup) and reducing growth signaling - a key longevity pathway.
Uniquely enters the nucleus under stress to directly regulate gene expression, activating antioxidant response genes via the Nrf2 pathway.
Improves glucose uptake and insulin sensitivity, reduces gluconeogenesis, and enhances fatty acid oxidation - mimicking exercise effects.
Scientific Pathways
AMPK Activation Pathway (Primary Mechanism)
MOTS-c → Cytoplasmic accumulation → AMPK activation
↓
├── Increased glucose uptake (GLUT4)
├── Enhanced fatty acid oxidation
├── Inhibition of gluconeogenesis
└── mTOR suppression → Autophagy activationNuclear Gene Regulation (Transcriptional Effects)
MOTS-c → Nuclear translocation (under stress) → Nrf2-ARE pathway
↓
Antioxidant gene expression
Metabolic reprogramming
Stress resistance genesKey Research: Lee C et al. (2015) discovered MOTS-c and characterized its AMPK-dependent metabolic effects in Cell Metabolism. PMID:25738459
Important Limitations
- No clinical trials — All therapeutic data is preclinical (mouse models)
- No receptor identified — Mechanism of AMPK activation not fully understood
- Most studies from one lab — Cohen lab produces majority of research
- Mouse-human translation uncertain — Metabolic differences between species
- Long-term effects unknown — Chronic mTOR suppression could have consequences
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
MOTS-c activates AMPK rapidly in cellular models. Nuclear translocation occurs under metabolic stress. Acute effects on glucose uptake observed in vitro within hours.
Mouse studies typically administer MOTS-c for days to weeks. Metabolic improvements (glucose tolerance, insulin sensitivity) observed within 1-2 weeks of treatment. Exercise increases circulating MOTS-c acutely.
Endogenous MOTS-c levels decline with age. Chronic effects of exogenous administration not characterized in long-term studies. No human pharmacokinetic data available for chronic dosing.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate MOTS-c product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining MOTS-c with other peptides. Based on published research and mechanistic considerations.
Humanin
SynergisticBoth are mitochondria-derived peptides with complementary mechanisms. MOTS-c focuses on metabolic regulation via AMPK while humanin provides cytoprotection. May offer combined longevity benefits.
Shlp-2
CompatibleBoth are MDPs encoded in mtDNA. Different target pathways - MOTS-c for metabolism, SHLP-2 for mitochondrial function. No interaction studies available.
Epithalon
CompatibleDifferent longevity mechanisms - MOTS-c targets AMPK/mTOR metabolic pathways while epithalon targets telomerase. No known interactions.
Ss-31
CompatibleBoth target mitochondrial function. SS-31 stabilizes cardiolipin while MOTS-c signals through AMPK. Potentially complementary mechanisms.
Semaglutide
CautionBoth affect glucose metabolism. MOTS-c activates AMPK while semaglutide is a GLP-1 agonist. Combined effects on blood sugar warrant monitoring.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare MOTS-c
MOTS-c Calculators
Related Peptides
Endoluten
Pineal cytamin, Pineal gland peptides, A-8 pineal peptides
A cytamin-class peptide supplement derived from pineal gland tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for pineal function and melatonin support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
FOXO4-DRI
FOXO4-D-Retro-Inverso, FOXO4-DRI Peptide, Proxofim
A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, selectively eliminating senescent cells (senolytic). Preclinical studies in aged mice demonstrated restored fitness, fur density, and renal function. No human clinical trials conducted. More selective than BCL-2 inhibitors but remains unproven in humans.
Glutathione
GSH, L-Glutathione, Reduced Glutathione +1 more
The master antioxidant and most abundant intracellular thiol in mammalian cells. This naturally occurring tripeptide (glutamate-cysteine-glycine) is essential for detoxification, immune function, and cellular protection. Extensively studied with strong mechanistic understanding and growing clinical evidence.
SHLP-6
Small Humanin-Like Peptide 6, SHLP6, Mitochondrial-Derived Peptide 6
A 22-amino acid mitochondria-derived peptide with the unique property of being pro-apoptotic—the opposite of its sister peptides humanin and SHLP-2. Discovered in 2016, SHLP-6 may have applications in cancer and senescent cell clearance. Research is very early-stage with minimal published data.
SS-31
Elamipretide, Bendavia, MTP-131
A first-in-class mitochondria-targeting tetrapeptide that binds cardiolipin on the inner mitochondrial membrane. Developed by Stealth BioTherapeutics for mitochondrial diseases, heart failure, and age-related macular degeneration. Phase 3 trials in primary mitochondrial myopathy did not meet primary endpoints, but Barth syndrome data was positive. Strong preclinical rationale with mixed clinical translation.